1 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple MyelomaBlood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myelomaActive, not recruitingPhase 22022-09-10NCT02415413